These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 34075537)

  • 1. The role of Interleukin-1 receptor antagonist as a treatment option in calcium pyrophosphate crystal deposition disease.
    Altomare A; Corrado A; Maruotti N; Cici D; Cantatore FP
    Mol Biol Rep; 2021 May; 48(5):4789-4796. PubMed ID: 34075537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 1β blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment.
    Diamantopoulos AP; Brodin C; Hetland H; Haugeberg G
    J Clin Rheumatol; 2012 Sep; 18(6):310-1. PubMed ID: 22832289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-centre retrospective case series of Anakinra for incident calcium pyrophosphate deposition disease.
    Lian A; Shandilya A; Riordan J
    Clin Rheumatol; 2023 Jul; 42(7):1833-1837. PubMed ID: 36913030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of calcium pyrophosphate crystal deposition disease: A systematic review.
    Parperis K; Papachristodoulou E; Kakoullis L; Rosenthal AK
    Semin Arthritis Rheum; 2021 Feb; 51(1):84-94. PubMed ID: 33360232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium pyrophosphate deposition (CPPD) disease - Treatment options.
    Stack J; McCarthy G
    Best Pract Res Clin Rheumatol; 2021 Dec; 35(4):101720. PubMed ID: 34756508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature.
    Ottaviani S; Brunier L; Sibilia J; Maurier F; Ardizzone M; Wendling D; Gill G; Palazzo E; Meyer O; Dieudé P
    Joint Bone Spine; 2013 Mar; 80(2):178-82. PubMed ID: 23022422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the therapeutic management of calcium pyrophosphate deposition disease.
    Voulgari PV; Venetsanopoulou AI; Drosos AA
    Front Med (Lausanne); 2024; 11():1327715. PubMed ID: 38529115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Narrative Review of Chondrocalcinosis: Clinical Presentation, Diagnosis, and Therapies.
    Kim SY; Afroz S; Gillespie H; Downey C
    Cureus; 2024 May; 16(5):e60434. PubMed ID: 38882993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis.
    Moltó A; Ea HK; Richette P; Bardin T; Lioté F
    Joint Bone Spine; 2012 Dec; 79(6):621-3. PubMed ID: 22658375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy for CPPD: Options and Evidence.
    Andrés M; Sivera F; Pascual E
    Curr Rheumatol Rep; 2018 Apr; 20(6):31. PubMed ID: 29675606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anakinra for Refractory Pseudogout in Patients with End-stage Renal Disease on Haemodialysis.
    Antoniadou C; Fytanidis N; Devetzis V; Kantartzi K; Papagoras C
    Mediterr J Rheumatol; 2024 Mar; 35(Suppl 1):58-62. PubMed ID: 38756932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium pyrophosphate deposition disease: clinical manifestations.
    Ferrone C; Andracco R; Cimmino MA
    Reumatismo; 2012 Jan; 63(4):246-52. PubMed ID: 22303531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis of calcium pyrophosphate deposition disease.
    Williams CJ; Rosenthal AK
    Best Pract Res Clin Rheumatol; 2021 Dec; 35(4):101718. PubMed ID: 34696986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Calcium pyrophosphate dihydrate crystal induced arthropathy].
    Announ N; Guerne PA
    Rev Med Suisse; 2007 Mar; 3(103):740-2, 744, 746. PubMed ID: 17458152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium pyrophosphate dihydrate crystal deposition disease.
    Bencardino JT; Hassankhani A
    Semin Musculoskelet Radiol; 2003 Sep; 7(3):175-85. PubMed ID: 14593559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologics in the treatment of calcium pyrophosphate deposition disease: a systematic literature review.
    Cipolletta E; Di Matteo A; Scanu A; Isidori M; Di Battista J; Punzi L; Grassi W; Filippucci E
    Clin Exp Rheumatol; 2020; 38(5):1001-1007. PubMed ID: 32359034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis and treatment of calcium pyrophosphate crystal-induced arthropathy].
    Announ N; Guerne PA
    Z Rheumatol; 2007 Nov; 66(7):573-4, 576-8. PubMed ID: 17932681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chondrocalcinosis due to calcium pyrophosphate deposition (CPPD). From incidental radiographic findings to CPPD crystal arthritis].
    Tausche AK; Aringer M
    Z Rheumatol; 2014 May; 73(4):349-57; quiz 358-9. PubMed ID: 24811359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The forgotten crystal arthritis: calcium pyrophosphate deposition.
    Ivory D; Velázquez CR
    Mo Med; 2012; 109(1):64-8. PubMed ID: 22428450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure.
    Announ N; Palmer G; Guerne PA; Gabay C
    Joint Bone Spine; 2009 Jul; 76(4):424-6. PubMed ID: 19289295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.